DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Non-viral mediated gene therapy in human cystic fibrosis airway epithelial cells recovers chloride channel functionality
Gene therapy strategies based on non-viral vectors are currently considered as a promising therapeutic option for the treatment of cystic fibrosis (CF), being liposomes the most commonly used gene carriers. Niosomes offer a powerful alternative to liposomes due to their higher stability and lower cytotoxicity, provided by their non-ionic surfactant and helper components. In this work, a three-formulation screening is performed, in terms of physicochemical and biological behavior, in CF patient derived airway epithelial cells. The most efficient niosome formulation reaches 28% of EGFP expressing live cells and follows caveolae-mediated endocytosis. Transfection with therapeutic cystic fibrosis transmembrane conductance regulator (CFTR) gene results in 5-fold increase of CFTR protein expression in transfected versus non-transfected cells, which leads to 1.5-fold increment of the chloride channel functionality. These findings highlight the relevance of niosome-based systems as an encouraging non-viral gene therapy platform with potential therapeutic benefits for CF., Authors wish to thank: ICTS “NANBIOSIS”, specifically the Drug Formulation Unit (U10) of the CIBER in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) for the intellectual and technical assistance; SGIker (UPV/EHU) for technical and human support; the Department of Education, University and Research of the Basque Country Government (Consolidated Groups, IT907-16), the Spanish Ministry of Science and Innovation (Grant PID2019-106199RB-C21); the Cystic Fibrosis Association of the Basque Country; the Unit of Viral Infections and Comparative Pathology at the University of Lyon 1 and UK Cystic Fibrosis Gene Therapy Consortium for kindly providing the gene constructs used in this work: pEGFP-CFTR and pGM169, respectively. M.S.R. thanks the University of the Basque Country (UPV/EHU) for the granted pre-doctoral fellowship (PIF17/79). I.V.B. thanks the University of the Basque Country (UPV/EHU) for the granted post-doctoral fellowship (ESPDOC19/47).
Funding source declaration
This work was supported by the University of Basque Country (UPV/EHU) (pre-doctoral grant PIF17/79 and post-doctoral grant ESPDOC19/47), the Department of Education, University and Research of the Basque Country Government (Consolidated Groups, IT907-16), the Spanish Ministry of Science and Innovation (Grant PID2019-106199RB-C21); and the Cystic Fibrosis Association of the Basque Country., Peer reviewed